Robin Reschke

18PUBLICATIONS
20CO-AUTHORS
Molecular targetsTumour immunologyCancer diagnosisGene and molecular therapyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Robin Reschke, Petra Budde, Hans-Dieter Zucht

|Dec 20, 2024
Prognostic Biomarkers in Evolving Melanoma Immunotherapy.

Robin Reschke, Alexander H Enk, Jessica C Hassel

|Oct 15, 2024
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).

Ahmed M Mousa, Alexander H Enk, Jessica C Hassel

|Aug 29, 2024
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.

Robin Reschke, Alexander H Enk, Jessica C Hassel

|Jun 27, 2024
Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.

Robin Reschke, Alexander H Enk, Jessica C Hassel

|Mar 28, 2024
Correction: Reschke, R.; Olson, D.J. Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce a "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy. Cancers 2022, 14, 2458.

Robin Reschke, Daniel J Olson

Pageof 3

Frequent Collaborators

5 joint publications

Mirjana Ziemer

4 joint publications

Jessica C Hassel

3 joint publications

Daniel J Olson

2 joint publications

Jovian Yu